Chinese Diagnostic Imaging Market to Reach More Than $2.5 Billion by 2016

Thanh Le | | Radiology Business | Business Intelligence
The Chinese diagnostic imaging market will grow to reach a value of more than $2.5 billion by 2016, according to the Millennium Research Group (MRG), a global authority on medical technology market intelligence. As part of the Chinese government's $125 billion New Medical Reform Plan, intended to provide affordable healthcare to the entire population by 2020, it will invest money to upgrade lower-tier rural hospitals and construct new facilities. As a result, higher-tier hospitals will be able to replace their outdated systems, while smaller, less affluent hospitals will be able to purchase systems for the first time, particularly more advanced modalities such as CT, MRI, and nuclear medicine systems. This will represent a significant sales opportunity for manufacturers of such systems, the report finds. Domestic competitors have a significant role in the market for analog X-ray and lower-end ultrasound systems. They have relatively lower production costs than multinationals. The large number of domestic competitors keep prices for these systems low, which makes them attractive for less-affluent hospitals and clinics. In 2011 Beijing Wandong Medical Equipment was the overall leader among domestic competitors. Each of the top three multinational competitors in China, GE Healthcare, Siemens Healthcare and Philips Healthcare, has shares in each of the market's segments: MRI, CT, X-ray, ultrasound and nuclear medicine. They can leverage their brand and establish strong customer relationships. Wealthy urban Chinese show a strong preference for known international brands, and this influences hospital system purchases. "The Chinese government also has an implementation initiative for positron emission tomography (PET)/CT systems," said MRG Analyst Michelle Chan, in the press release. "They plan to increase licensing and install many new PET/CT systems by 2016. This initiative will initially be limited by the need to establish a radiopharmaceutical supply chain. Once that infrastructure is in place, we can expect to see a rapid increase in sales, probably by 2015." For the full MRG Report, click here.

Thanh Le

Related Content

Orano Med breaks ground on $265M thorium production site
Image-interpretation market scoreboard: Radiologists 72%, others 28%
Lantheus lands rights to budding radiopharmaceuticals for initial outlay of $35M
17 short-term strategies to address the national radiologist shortage
‘SR’ onboards another independent practice, its 1st in the Natural State
Analysis: Allied radiology professionals generate millions of dollars per year in indirect revenues alone

Around the web

Health Imaging
Nearly $800,000 settlement offered to family of man who died during MRI exam

The patient, who was being cared for in the ICU, was not accompanied or monitored by nursing staff during his exam, despite being sedated.

Cardiovascular Business
Global shortage of nuclear imaging isotopes may be over

The nuclear imaging isotope shortage of molybdenum-99 may be over now that the sidelined reactor is restarting. ASNC's president says PET and new SPECT technologies helped cardiac imaging labs better weather the storm.

Cardiovascular Business
‘A huge win’: CMS significantly increases Medicare payments for cardiac CT

CMS has more than doubled the CCTA payment rate from $175 to $357.13. The move, expected to have a significant impact on the utilization of cardiac CT, received immediate praise from imaging specialists.